Diligence memo · auto-generated · as of July 3, 2026
Mira Dx, Inc.
Mira Dx, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Mira Dx, Inc. operates in Biotechnology, based in New Haven.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Mira Dx, Inc. has raised $6.2M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.2M on 2009-09-01.
Most recent recorded round closed around 2009-09-01.
Valuation (modeled)modeled
Provath models Mira Dx, Inc. at approximately $150M (range $4.5M–$817M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.51× the median modeled value of Series A Biotechnology companies in 2007–2009 (35 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 16.8 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round was 2.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 48% of Biotechnology peers (4293 compared).
Modeled value ranks above 66% of those peers.
Closest niche peers: Complete Genomics Inc, BioTrove, Inc., Aliva Biopharmaceuticals, LLC, Molecular Biometrics Inc, Bioimagene Inc.
Peoplefiled
4 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.